The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. [electronic resource]
Producer: 20180822Description: 38-46 p. digitalISSN:- 1941-837X
- Antithrombins -- economics
- Atrial Fibrillation -- complications
- Cohort Studies
- Cost-Benefit Analysis -- economics
- Dabigatran -- economics
- Female
- Humans
- Male
- Markov Chains
- Netherlands
- Quality-Adjusted Life Years
- Retrospective Studies
- Risk Assessment
- Thromboembolism -- etiology
- Treatment Outcome
- Vitamin K -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.